Abstract:Objective To evaluate the efficacy and safety of two dose levels of gliclazide MR (30 mg/d and 60 mg/d) in the treatment of Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM),and its effects on insulin resistance and β-cell function.Methods A total of 120 subjects with newly diagnosed T2DM were randomized to receive 30 mg/d (Group 30 mg)or 60 mg/d (Group 60 mg) of gliclazide MR in the proportion of 1 to 1 according to random number table for 16 weeks.Glycated hemoglobin A1c (HbA1c)was measured as major efficacy index,and secondary indices such as fasting plasma glucose (FPG),two-hour postprandial plasma glucose (2 h PG),7-point glucose profile,area under curve of insulin (AUC1NS),insulin sensitivity index (SEN)and the indices of the β-cell secretory function [including early insulin secretion index (ΔI30/ΔG30),basic insulin secretion index (HOMA-β)and modified β-cell function (MBCI)].Safety was assessed by adverse events (AEs),and so on.The difference of the measurement data was compared with the t test.The Wilcoxon test was used to assess the statistical difference among the groups.Results At 16 weeks,the change from baseline in HbA 1 c was-1.2％± 1.1％ in the Group 30 mg and-2.2％± 1.4％ in the Group 60 mg,intergroup comparison with baseline HbA1c as a covariate showed that the descent range in the Group 60 mg was more significant (F=4.2,P=0.04).There was no intergroup difference in the change from baseline of FPG,2 hPG and 7-point glucose profile.Also,no intergroup difference was noted in the change from baseline of AUCINS and ΔI30/ΔG30.After treatment,the index of HOMA-β had a significant increasing amplitude in the Group 60 mg compared to that in the Group 30 mg (t=1951.0,P=0.04).The incidence of hypoglycemia related to study drug was 10.5％ (6/57)in the Group 30 mg and 16.1％(9/56)in the Group 60 mg.To the end of follow-up,no significant difference in the body mass index was found between the two groups[(24.8±2.6)kg/m2 in Group 30 mg and(24.2±2.5)kg/m2 in Group 60 mg,t=1.09,P＞0.05].Conclusion The dose regimen of gliclazide MR 60 mg/d is superior to 30 mg/d in the improvement of HbA1c and β-cell function for Chinese patients with newly diagnosed T2DM ;however,dosage of 60 mg/d increases the incidence of slight hypoglycemia events.Thus,for patients with newly diagnosed T2DM,selection of initial therapy dose should be patient-tailored,based on clinical features of β cell function and hypoglycemia risks.

Comparison of Efficacy and Quality of Life in Type 2 Diabetics Treated with Controlled-Release-gliclazide and Ordinary Gliclazide Tablets

Efficacy and Safety in Type 2 Diabetes Treated by Controlled-release-gliclazide in Comparison with Gliclazide

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial.

Clinical Effects of Gliclazide Sustained-Release Tablets on Type 2 Diabetes Mellitus

Efficacy and Safety Between Two Dosages of Gliclazide Modified Release Tablets (30 Mg and 60 Mg Once Daily) in the Treatment of Patients with Newly Diagnosed Type 2 Diabetes

Efficacy and safety of rosiglitazone hydrochloride in the treatment of patients with type 2 diabetes mellitus

The glycemic control in Chinese type 2 diabetic out-patients receiving oral antidiabetic agents and the efficacy and safety of optimized modified-release gliclazide treatment

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

Comparison of Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Clinical Efficacy and Safety

Clinical efficacy of glimepiride combined with pioglitazone on glycemic control in type 2 diabetes patients

PDG8 EFFICACY OF PHARMACOLOGICAL MONOTHERAPIES FOR TYPE 2 DIABETES IN CHINA

The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus]

Comparision of glimepiride and glibenclamide on cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

Efficacy and Safety of Chiglitazar in Type 2 Diabetes:A Multi?center, Randomized, Double?blind, and Parallel Group Clinical Trial

Clinical Study of Controlled-Release formula of Glipizide in the Treatment of Coronary Artery Disease Complicated with Type 2 Diabetes Mellitus

Comparison of the safety and clinical efficacy of glucagon-like peptide-1 receptor agonist and α-glucosidase inhibitor among Chinese people with type 2 diabetes

[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].

Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.

Efficacy and Safety of Pioglitazone Hydrochloride in Treating Type 2 Diabeter

Pioglitazone in Treatment of Type 2 Diabetes:A Phase Ⅱ Clinical Trial

Comparison of the effect of different short-term intensive anti-diabetic therapies on newly diagnosed type 2 diabetic patients.